Verona Pharma plc: auditor change — Verona Pharma dismisses PwC, appoints EY as auditor subject to 2024 AGM vote

Verona Pharma plc

Audit committee dismissed PwC on Dec 14, 2023; approved EY engagement for FY 2024 subject to shareholder appointment at 2024 AGM.
No disagreements or reportable events between Verona and PwC during FY 2021-2022 and interim period through Dec 14, 2023.
PwC's reports on FY 2022 and FY 2021 financial statements were unqualified, containing no adverse opinion or modification.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Verona Pharma plc engaged Ernst & Young LLP as its auditor.

Action: engagement
Auditor: Ernst & Young LLP

Exact text from the filing

approved the engagement of Ernst & Young LLP ("EY") to serve as the Company’s independent registered public accounting firm

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Verona Pharma plc dismissed PricewaterhouseCoopers LLP as its auditor.

Action: dismissal
Auditor: PricewaterhouseCoopers LLP
Successor: Ernst & Young LLP

Exact text from the filing

dismissed PricewaterhouseCoopers LLP ("PwC") and approved the engagement of Ernst & Young LLP ("EY") to serve as the Company’s independent registered public accounting firm

View on SEC.gov

Browse all auditor changes →

Source: SEC EDGAR

accession 0001104659-23-126869

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.